A randomised observer masked clinical study was conducted to assess the additive effect of latanoprost (13,14-dihydro-17-phenyl-18,19, 20-trinorprostaglandin F2a-isopropylester) 
Investigations using animal models have shown that prostaglandins (PG) can effectively lower intraocular pressure (IOP) in several species including primates. '-5 Although subsequent studies in normotensive and glaucomatous eyes showed that topical application of PGF2a6 and prostaglandin F2a-isopropylester (PGF2a-IE)'-9 can effectively lower IOP in human subjects, dose dependent conjunctival hyperaemia and local irritation prevented their use. 6 Recently it has been reported that certain phenyl substituted prostaglandin analogues induce an effective IOP reduction with fewer side effects.10 In particular, PhXA34 (13,14-dihydro-15(R,S)-17-phenyl-18,19,20- trinor-PGF2a-isopropylester)" 12 and latanoprost'>'5 (its 15-R epimer) have been reported to decrease IOP at low concentrations with fewer side effects. Two recent studies'617 showed a marked additive effect of PGF2,-IE when combined with timolol. We were, therefore, interested in the combination therapy with latanoprost and timolol.
The purpose of this study was to evaluate the efficacy and side effect profile of latanoprost as single therapy and in combination with the 13 adrenergic antagonist timolol. The trial was designed as a randomised, observer masked study evaluating the additive effect of latanoprost and timolol in two parallel groups with two consecutive treatment periods of 1 week each. Before the study patients underwent a washout period of 8 days or longer for sympathicomimetics, 14 days or longer for cholinergic agents, and 21 days or longer for adrenergic antagonists. In the first week of the study, patients in group A administered one drop (approx 35 gil) of latanoprost in both eyes between 700 am and 900 am and one drop between 700 pm and 900 pm. In the second week timolol was administered after latanoprost with a 5 minute interval.
Patients in group B started with timolol, one drop in both eyes between 7 00 am and 9 00 am and one drop between 700 pm and 900 pm. After the first week latanoprost was added 5 minutes after timolol was administered.
Commercially available timolol (Timoptol 0-5%, MSD, Haarlem, the Netherlands) was used and latanoprost (0-006%: 60 ,ug/ml) was provided by Kabi Pharmacia, Uppsala, Sweden.
All IOP measurements were performed using a Goldmann applanation tonometer, with the scale masked for the investigator. The study was approved by the ethics review board of the Academic Medical Center, Amsterdam and each patient gave written informed consent before entering the study. The study was performed in accordance with the principles adopted by the 18th World Medical Assembly, Helsinki, Finland, 1964 and later revisions.
Results
Ten patients were allocated to latanoprost treatment (group A) and 10 patients to timolol treatment (group B). One patient in group A was excluded because it was found out that the patient had undergone only 2 days instead of 2 weeks washout of pilocarpine and acetazolamide. There were no major differences between the groups with regard to the demographic characteristics such as mean age and male/female ratio, but IOP at day 0 differed markedly between the groups (Table 1 ).
In the group using latanoprost maximum IOP lowering effect was-seen on day 2 (Fig 1) . On day 7 an IOP reduction of 8-9 (2-5) mm Hg (p<0-01) was observed in the latanoprost group compared with a reduction of 5 9 (2-3) mm Hg (p<0-01) in the timolol group (31% and 24% respectively). This difference in IOP reduction between the groups was not significant. The combined therapy revealed an additional IOP reduction compared with either drug administered alone. Latanoprost added to timolol further reduced IOP on day 14 compared with day 7 2-6 (2 2) mm Hg (p<0-01) and timolol added to latanoprost further reduced IOP 2-6 (I 1) mm Hg (p<0-01).
Conjunctival hyperaemia compared with baseline was especially seen in the latanoprost treatment group on day 2 (Table 2) . On day 7, less conjunctival hyperaemia was registered than on day 2. When latanoprost was added to timolol conjunctival hyperaemia increased slightly compared with day 7, being more pronounced on day 9. No changes in hyperaemia were observed when timolol was added to latanoprost. The difference in hyperaemia between the two groups was, however, not statistically significant on days 2 and 7 (p>0 05, Wilcoxon rank sum test).
Latanoprost was well tolerated in the study. Stinging sensations after both latanoprost and timolol were noted in a few patients. The heart rate was reduced with 5-8 (6 9) min-' (p<005) onday7and6-9(8 8)min-' (p<005)onday 14 compared with day 0 in the timolol-latanoprost group. There was no significant effect on the systolic or diastolic blood pressure in either group.
Discussion
Previous studies using other prostaglandin analogues such as PGF2a,-IE were hampered by clinically unacceptable grades of conjunctival hyperaemia, local irritation, and pain sensation when optimal IOP lowering doses were administered.6 Latanoprost, a new PGF2,1 analogue, seems to have markedly fewer side effects as reported in previous studies.9 13-I5 The main mechanism of action to account for the reduction in IOP following administration of prostaglandin F2a and its analogues is thought to be an increase in uveoscleral outflow'8-20 and not The data indicate the numbers of patients with a given hyperaemia score.
seen mainly during the first week of treatment.'4 As a single therapy latanoprost effectively reduced IOP in this study. Maximum IOP lowering effect was observed after 2 days of treatment, the decline in IOP being 42%; after 
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